Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

AI Stock Picker
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
Stock Chart Patterns
Earnings Trading
AI Screener

Resources

Resources

Blog
Earnings
Tutorial
Partner Program

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DRUG
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
DRUG
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

DRUG Similar Chart Price Prediction

The price of DRUG is predicted to go up 4.11%, based on the high correlation periods with FET. The similarity of these two price pattern on the periods is 95.85%.

stocks logo

DRUG

stocks logo

FET

Up: 4.11%Similarity: 95.85%

DRUG Revenue Forecast

DRUG EPS Forecast

DRUG FAQs

What is bull’s view on DRUG?

DRUG stock closed at $34 on January 31, 2025, with a 4.97% gain during regular trading hours. Analysts are bullish, with Piper Sandler assigning a $93 price target, citing the potential of its lead drug BMB-101 for drug-resistant epilepsy. The stock's recent momentum and strong analyst support suggest significant upside potential.

What is bear's view on DRUG?

DRUG stock currently trades at $33.94, significantly below the $93 price target set by analysts, indicating potential overvaluation concerns. Despite recent leadership changes, the company’s financials and market sentiment do not yet justify such a high valuation. Bears argue that the stock's 4.97% recent gain is speculative and lacks fundamental support, making it vulnerable to corrections.

What is DRUG eps forecast for next quarter？

The market consensus for DRUG's eps in the upcoming quarter is projected to be approximately $0.55 CAD.

DRUG VS S&P500

Ask Intellectia about DRUG

DRUG Analyst's Forecast

Yasmeen Rahimi

Piper Sandler

Buy

2025-01-23

Price Target

$93

Upside

+188.1%

Piper Sandler initiated coverage of Bright Minds Biosciences with an Overweight rating and $93 price target. The firm believes the company's lead asset, BMB-101, is a "differentiated" G-protein biased 5-HT2C agonist positioned to drive sustained efficacy in drug-resistant epilepsies with clean safety. Piper sees BMB-101 as a more potent 5-HT2C agonist compared to bexicaserin with no beta-arrestin recruitment.
Charles Duncan

Cantor Fitzgerald

Buy

2025-01-10

Price Target

n/a

Downside

0%

Joel Beatty

Baird

Buy

2024-11-25

Price Target

$75

Upside

+77.26%

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
AI Stock PickerFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisStock Chart PatternsEarnings TradingAI Screener
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free

Hot Stocks

stocks logo

NFE

New Fortress Energy Inc

$10.9
-2.42%
stocks logo

BKH

Black Hills Corp

$59.79
0.23%
stocks logo

IRT

Independence Realty Trust Inc

$20.61
1.03%
stocks logo

AHR

American Healthcare REIT Inc

$27.75
1.61%
stocks logo

ASAN

Asana Inc

$19.82
-4.67%
stocks logo

VRNA

Verona Pharma PLC

$65.6
-3.47%
stocks logo

GBTG

Global Business Travel Group Inc

$8.55
0.00%
stocks logo

RDNT

RadNet Inc

$60.16
1.16%
stocks logo

POR

Portland General Electric Co

$44.31
-0.11%
stocks logo

IDCC

InterDigital Inc

$209.69
-0.81%